Kyle Doherty

Articles

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024

NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.

China’s NMPA Grants Priority Review to Sintilimab Plus Fruquintinib in pMMR/Non–MSI-H Advanced Endometrial Cancer

April 2nd 2024

The new drug application for sintilimab plus fruquintinib has been granted priority review by the NMPA for pMMR/non-MSI-H advanced endometrial cancer.

Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency

April 2nd 2024

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

Durvalumab Plus Guadecitabine Shows PFS Benefit in Cohort of Patients With ccRCC

April 1st 2024

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Clinicians Express Reservations Around Ethical Issues of AI in Cancer Care

April 1st 2024

A survey of practicing oncologists in the United States revealed that clinicians have ethical concerns surrounding the use of AI in cancer care.

CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL

March 29th 2024

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

ASCO GI Updates Provide Window Into Evolving HCC Treatment Paradigm

March 28th 2024

Experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 Gastrointestinal Cancers Symposium.

Japan’s MHLW Approves Zolbetuximab in CLDN18.2-Positive Gastric Cancer

March 26th 2024

The Japanese Ministry of Health, Labour and Welfare has approved zolbetuximab for CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.

Handling Parenting Pressures

March 26th 2024

Recent report details the issues early-career oncologists experience regarding parental leave.

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

March 22nd 2024

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.

Innovation Is the Answer to Making Progress Against Cancer

March 22nd 2024

Shanta Dhar, PhD, FRSC, discusses the significance of being named a fellow of the National Academy of Inventors for her research in prostate cancer.

Ribociclib Plus Nonsteroidal Aromatase Inhibitor Extends iDFS in HR+/HER2– Early-Stage Breast Cancer

March 22nd 2024

Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.

Preclinical Data Suggest XPO1 Offers Potential Treatment Pathway in TP53 Wild-Type LGSOC and CCOC

March 20th 2024

Treatment with XPO1 inhibitors could be effective and warrants further investigation in low-grade serous and clear cell ovarian cancer.

NT219 Plus Cetuximab Demonstrates Efficacy, Tolerability in SCCHN

March 20th 2024

NT219 in combination with cetuximab was safe and effective in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

MRD-Directed Ibrutinib Plus Venetoclax Bests FCR in CLL

March 20th 2024

MRD-guided ibrutinib plus venetoclax displays PFS and OS benefits over fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

Raising Hope

March 18th 2024

Grant winner Tyler Miller, MD, PhD, outlines innovative plans for glioma research.

Novel CAR T-Cell Therapy Displays Activity in Glioblastoma

March 18th 2024

Treatment with a next-generation CAR T-cell agent displayed early efficacy in a small group of patients with glioblastoma.

Disparities in Care Outcomes Persist Between Black and White Patients With Endometrioid Endometrial Carcinoma

March 18th 2024

Black patients with endometrioid endometrial carcinoma experienced an increased risk of death and lower enrollment in clinical trials vs White patients.

Mutter Discusses Partial Breast Irradiation in Low-Risk Breast Cancer

March 15th 2024

Robert W. Mutter, MD, discusses the nuances of partial breast irradiation in early-stage breast cancer.

Venetoclax Displays Durable Efficacy in Relapsed/Refractory CLL

March 14th 2024

Patients with relapsed/refractory chronic lymphocytic leukemia experienced long-lasting responses with venetoclax.